June 26, 2013 by Rachel Swan SF EXAMINER A legal spat that includes South San Francisco biotech giant Genentech has the potential to cost patients who need several drug treatments, including a handful for cancer treatment. Citing derelict royalty payments…
Tag: Biopharmaceutica
Theravance to proceed with plan to split business
SOUTH SAN FRANCISCO, Calif. (AP) —June 17, 2013 Bloomberg Business Week Drug developer Theravance Inc. plans to split into two independent, publicly traded companies after a royalty agreement it had ironed out with Irish drugmaker Elan Corp. PLC fell through.…
VistaGen Therapeutics Inc.Advancements
VistaGen Therapeutics Presents CardioSafe 3D(TM) and LiverSafe 3D(TM) Developments at International Society of Stem Cell Research’s 11th Annual Meeting VistaGen Therapeutics Inc. VSTA | 6/17/2013 10:29:22 AM VistaGen Therapeutics Presents CardioSafe 3D(TM) and LiverSafe 3D(TM) Developments at International Society of…
City Council Agenda June 12, 2013 – Public Hearing
Public Hearing On Genentech Master Plan Changes South San Francisco, CA June 7, 2013 AGENDA CITY COUNCIL CITY OF SOUTH SAN FRANCISCOREGULAR MEETING MUNICIPAL SERVICES BUILDING COMMUNITY ROOMWEDNESDAY , JUNE 12, 2013 7:00 P.M. PEOPLE OF SOUTH SAN FRANCISCOYou…
Titan Pharmaceuticals, Inc receives response letter from FDA
TITAN PHARMACEUTICALS RECEIVES COMPLETE RESPONSE LETTER FROM THE FDA FOR PROBUPHINE NEW DRUG APPLICATION SOUTH SAN FRANCISCO, CA, April 30, 2013 – FOR IMMEDIATE RELEASE Titan Pharmaceuticals, Inc. (OTCBB: TTNP) announced that the U.S. Food and Drug Administration (FDA) has…
FDA Rejection of Titan’s Probuphine Looks Like a Mugging
SOUTH SAN FRANCISCO, Calif. (TheStreet) BY Adam Feuerstein | 05/01/13 – 10:19 AM EDT) — The U.S. Food and Drug Administration came down hard on Titan Pharmaceuticals (TTNP), rejecting its Probuphine implantable therapy for opioid dependence and requesting a lot…
Theravance to separate company into two benefits public trading
Theravance Announces Plan to Separate Late-Stage Partnered Respiratory Assets From Biopharmaceutical Operations Designed to Unlock Potential Value, Facilitate Return of Capital to Stockholders and Further Strategy of Advancing Medicines That Address Unmet Medical Needs SOUTH SAN FRANCISCO, CA — (Marketwired)…
$13.6 billion Life Tech deal raises questions for workers, shareholders
By Ron Leuty Reporter- San Francisco Business Times Apr 15, 2013, 1:10pm PD Thermo Fisher Scientific Inc. will buy Life Technologies Corp. — formed only four years ago with the merger of Foster City’s Applied Biosystems Inc. and Invitrogen Corp. —…
Portola Pharmaceuticals seeks $115 million IPO – Ron Leuty Reporting
Portola Pharmaceuticals Inc. will seek $115 million in one of biotech’s largest IPOs this year. Ron Leuty Reporter- San Francisco Business Times The South San Francisco drug developer, long seen as a prime candidate for an initial public offering, said…